久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

美國Covance Research Products(CRP)   
CRP，即Covance Research Products，專為生物醫學和生物制藥學產業提供產品和服務，產品涵蓋實驗動物、抗體、試劑盒等，尤以神經科學產品見長。
三十年來，位于美國的Covance Research Products公司為生物醫學研究提供實驗動物和相關服務。CRP還提供抗體產品和相關服務，轉基因克隆管理服務并進行臨床外科學設備研究。

CRP是第一家建立血統清晰的商業用克隆兔的公司，成功的建立了Caesarean來源的的克隆兔，首先生產雜交兔,并為畸胎學研究人員提供商業化定時交配兔。從只擁有單一的飼養場所發展至今，CRP已經擁有五個養殖點，包括家兔，豚鼠,犬和靈長類動物。自1998年11月與伯克利抗體公司(BabCO)合并后，CRP在抗體供應和服務業務上進展迅速，并擴大了其在創新外科方面的研究能力。

Covance Pharmaceutical Research and Development (Shanghai) Co., Ltd.
Building #3, No. 3377 Kangxin Rd.
SIMZ Pudong
Shanghai 201318, China


CRP公司提供已經獲得ISO9002，AAALAC等認證的儀器設備，為藥物開發客戶提供高質量、高效率的產品和服務，是CRP一貫的宗旨。

關于CRP的產品和服務

實驗動物
犬類：beagles,mongrels,mini-mongrels,hounds
兔類：New Zealand White，Dutch Belted，Watanabe，Californian，Inbred NZW
豚鼠:突變鼠
靈長類動物：Cynomolgus,Rhesus
豬：Domestic Yorkshire
CRP能夠利用各種各樣的外科手術對其訂購的動物進行手術，除此以外，CRP公司還提供行為加強服務，例如對實驗動物進行踏車訓練或適應實驗環境的相關訓練。

創新外科和研究服務
CRP提供一系列的創新外科和研究服務，支持藥物開發和醫學設備研究，除此以外還進行GLP研究。安裝動物的動脈導管和醫學設備開發在7500平方英尺的外科實驗室完成。

抗體產品和服務
CRP提供創新抗體產品和定制抗體服務。客戶可以與本公司擁有廣泛經驗的科學團隊合作而受益，公司能幫助客戶選擇有效抗體產品，提供客戶自定義服務。
定制服務包括
多克隆抗體產品
雜交細胞系的開發
單克隆抗體的開發(體外)
新型抗體產品家族
抗原決定簇抗體
細胞標記物和受體
細胞骨架和細胞表面蛋白
轉錄因子和信號傳導

Covance — one of the world's largest and most comprehensive drug development services companies — has the people, global resources and problem-solving culture to respond to pharmaceutical and biotechnology clients' toughest drug development challenges.

We provide a portfolio of preclinical and clinical development and commercial service offerings — delivered through industry-leading nonclinical testing services, the world's largest central laboratory network, and a global team of clinical trial professionals.
About Covance
Covance Company Overview

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.5 billion, global operations in more than 20 countries, and more than 8,900 employees worldwide. Offering drug development solutions from preclinical through commercialization, Covance is a world-class provider of the following service lines:

Research products
Antibody products and services
Nonclinical development services
Risk management services
Clinical pharmacology services
Central laboratory/Covance local laboratory services
Cardiac safety services
Clinical development services
Commercialization services
Covance — Meeting Your Needs

With a commitment to meeting your needs, Covance offers unparalleled expertise, experience and results. Covance knows the significant pressures pharmaceutical and biotechnology companies of all sizes face in developing and launching drugs backed by strong data.

With a business built around your needs, our streamlined approach to drug development means high quality, error-free data designed to help bring your drug to market as quickly, safely and cost effectively as possible, including:

Proving early safety
Conducting first in human studies
Conducting proof of concept studies
Proving clinical safety and efficacy
Filing for marketing approval
Launching and marketing a drug
Ensuring patient safety and access
Managing risk
Managing over 15,000 clinical trial protocols in 100 countries on 6 continents, Covance provides the experience and exceptional customer service to advance your compound along the drug development continuum. Strategic partnerships built on decades of success — Covance is dedicated to helping bring your miracles to market sooner.
In the late 1980s and early 1990s, Corning, Incorporated acquired numerous best-of-class drug development companies, some with roots dating back to the 1940s. In January 1997, Corning spun off these businesses as one publicly-traded, independent company called Covance Inc. [NYSE: CVD].

Covance Today
Today, from its corporate headquarters in Princeton, NJ, Covance has grown into one of the world's largest and most respected global drug development services companies. Moving forward, Covance continues to broaden its capabilities by strategic acquisition and in-house development. The Company's primary focus is serving the pharmaceutical and biotech industries offering a broad range of services — from nonclinical research to clinical development to commercialization services.